ISM3830 / Insilico Medicine - LARVOL DELTA

Cbl-b inhibition with ISM3830 restores innate and adaptive immunity and demonstrates antitumor activity against solid tumors in vitro and in vivo (AACR 2026) - "These data together demonstrate ISM3830 potently activates the innate and adaptive immune responses, sustains antitumor efficacy in animal models, and synergizes with other immune checkpoint inhibitors while maintaining favorable pharmacokinetic and safety profile suitable for clinical development. This work supports the further development of ISM3830 as an immune checkpoint inhibitor to treat various solid tumors."

Preclinical • Oncology • Solid Tumor • IFNG • PD-L1

Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor immunotherapy (Insilico Medicine Press Release) - "In preclinical studies, ISM3830 showed robust in vivo anti‑tumor activity in multiple murine models, induction of long‑term tumor immunity, and combination potential with immune checkpoint inhibitors, chemotherapies and targeted agents. IND‑enabling studies are being initiated to support first‑in‑human evaluation in patients with advanced solid tumors."

Pipeline update • Preclinical • Solid Tumor